 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of [0m
[34mhospitalization?[0m
 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or decrease the risk of [0m
[32mhospitalization?[0m
 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ALENDRONATE SODIUM: dosage_and_administration: [0m[1;31m3[0m[31m Important Administration Instructions Instruct patients to do the following to assure adequate drug absorption and to decrease the risk of [0m
[31mesophageal adverse reactions: i. Take BINOSTO upon arising for the day and at least [0m[1;31m30[0m[31m minutes before the first food, beverage, or medication of the day. Patients should not swallow the undissolved [0m
[31meffervescent tablet, should not chew the effervescent tablet or allow the effervescent tablet to dissolve in their mouths because of the risk for oropharyngeal irritation [0m[31m. Dissolve the effervescent [0m
[31mtablet in [0m[1;31m4[0m[31m ounces room temperature plain water only [0m[1;31m([0m[31mnot mineral water or flavored water[0m[1;31m)[0m[31m. ii. Wait at least [0m[1;31m5[0m[31m minutes after the effervescence stops and then stir the buffered solution for [0m
[31mapproximately [0m[1;31m10[0m[31m seconds and ingest. iii. Avoid lying down for at least [0m[1;31m30[0m[31m minutes after taking BINOSTO and until after their first food of the day. iv. ALENDRONATE SODIUM: dosage_and_administration: [0m
[31mDo not take BINOSTO at bedtime or before arising for the day. Failure to follow these instructions may increase the risk of esophageal adverse reactions [0m[31m . [0m[1;31m2.4[0m[31m Recommendations for Calcium and Vitamin [0m
[31mD Supplementation Instruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate [0m[31m . Patients at increased risk for vitamin D insufficiency [0m[1;31m([0m[31me.g., over the age of [0m[1;31m70[0m[31m [0m
[31myears, nursing home-bound, or chronically ill[0m[1;31m)[0m[31m may need vitamin D supplementation. Patients with gastrointestinal malabsorption syndromes may require higher doses of vitamin D supplementation and [0m
[31mmeasurement of [0m[1;31m25[0m[31m-hydroxyvitamin D should be considered. [0m[1;31m2.5[0m[31m Administration Instructions for Missed Doses If the once-weekly dose is missed, instruct patients to take one dose on the morning after [0m
[31mthey remember. ALENDRONATE SODIUM: dosage_and_administration: They should not take [0m[1;31m2[0m[31m doses on the same day but should return to taking one dose once a week, as originally scheduled on their chosen [0m
[31mday.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: clinical_pharmacology: [0m[1;31m12[0m[31m CLINICAL PHARMACOLOGY [0m[1;31m12.1[0m[31m Mechanism of Action Animal studies have indicated the following mode of action. At the cellular level, alendronate [0m
[31mshows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of [0m
[31mactive resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m [0m
[31mH[0m[1;31m][0m[31malendronate in bone showed about [0m[1;31m10[0m[31m-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined [0m[1;31m6[0m[31m and [0m[1;31m49[0m[31m days after [0m[1;31m[[0m[31m [0m[1;31m3[0m[31m H[0m[1;31m][0m[31malendronate administration in rats and mice, [0m
[31mrespectively, showed that normal bone was formed on top of the alendronate, which was incorporated inside the matrix. ALENDRONATE SODIUM: clinical_pharmacology: While incorporated in bone matrix, [0m
[31malendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats [0m
[31mshowed that alendronate treatment reduces bone turnover [0m[1;31m([0m[31mi.e., the number of sites at which bone is remodeled[0m[1;31m)[0m[31m. In addition, bone formation exceeds bone resorption at these remodeling sites, leading [0m
[31mto progressive gains in bone mass. [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing [0m
[31mcells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled during bone [0m
[31mturnover. ALENDRONATE SODIUM: clinical_pharmacology: Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can [0m
[31mbe confirmed by the finding of low bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis [0m
[31moccurs in both males and females but is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. These changes [0m
[31mresult in progressive bone loss and lead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to [0m
[31mage [0m[1;31m90[0m[31m, the risk of hip fracture in white women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. ALENDRONATE SODIUM: clinical_pharmacology: It is estimated that approximately [0m[1;31m40[0m[31m% [0m
[31mof [0m[1;31m50[0m[31m-year-old women will sustain one or more osteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial[0m
[31mmorbidity, disability, and mortality. Daily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent [0m
[31minhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. [0m
[31mThese biochemical changes tended to return toward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. [0m
[31mALENDRONATE SODIUM: clinical_pharmacology: Long-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, [0m
[31mdeoxypyridinoline and cross-linked N-telopeptides of type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. Similar [0m
[31mdecreases were seen in patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early[0m
[31mas [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with alendronate sodium. ALENDRONATE SODIUM: clinical_pharmacology: In osteoporosis treatment[0m
[31mstudies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone formation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by [0m
[31mapproximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In osteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by [0m
[31mapproximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively. Similar reductions in the rate of bone turnover were observed in postmenopausal women during one-year studies with once weekly alendronate sodium [0m[1;31m70[0m[31m mg for the[0m
[31mtreatment of osteoporosis and once weekly alendronate sodium [0m[1;31m35[0m[31m mg for the prevention of osteoporosis. These data indicate that the rate of bone turnover reached a new steady state, despite the [0m
[31mprogressive increase in the total amount of alendronate deposited within bone. ALENDRONATE SODIUM: clinical_pharmacology: As a result of inhibition of bone resorption, asymptomatic reductions in serum[0m
[31mcalcium and phosphate concentrations were also observed following treatment with alendronate sodium. In the long-term studies, reductions from baseline in serum calcium [0m[1;31m([0m[31mapproximately [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m and [0m
[31mphosphate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m to [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m were evident the first month after the initiation of alendronate sodium [0m[1;31m10[0m[31m mg. No further decreases in serum calcium were observed for the five-year duration of [0m
[31mtreatment; however, serum phosphate returned toward prestudy levels during years three through five. Similar reductions were observed with alendronate sodium [0m[1;31m5[0m[31m mg/day. In one-year studies with once [0m
[31mweekly alendronate sodium [0m[1;31m35[0m[31m and [0m[1;31m70[0m[31m mg, similar reductions were observed at [0m[1;31m6[0m[31m and [0m[1;31m12[0m[31m months. The reduction in serum phosphate may reflect not only the positive bone mineral balance due to alendronate [0m
[31msodium but also a decrease in renal phosphate reabsorption. ALENDRONATE SODIUM: clinical_pharmacology: Osteoporosis in Men Treatment of men with osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day for two [0m
[31myears reduced urinary excretion of cross-linked N-telopeptides of type I collagen by approximately [0m[1;31m60[0m[31m% and bone-specific alkaline phosphatase by approximately [0m[1;31m40[0m[31m%. Similar reductions were observed in [0m
[31ma one-year study in men with osteoporosis receiving once weekly alendronate sodium [0m[1;31m70[0m[31m mg. [0m[1;31m12.3[0m[31m Pharmacokinetics Absorption Relative to an intravenous [0m[1;31m([0m[31mIV[0m[1;31m)[0m[31m reference dose, the mean oral bioavailability[0m
[31mof alendronate in women was [0m[1;31m0.64[0m[31m% for doses ranging from [0m[1;31m5[0m[31m to [0m[1;31m70[0m[31m mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the [0m[1;31m10[0m[31m mg tablet in[0m
[31mmen [0m[1;31m([0m[1;31m0.59[0m[31m%[0m[1;31m)[0m[31m was similar to that in women when administered after an overnight fast and [0m[1;31m2[0m[31m hours before breakfast. ALENDRONATE SODIUM: clinical_pharmacology: BINOSTO [0m[1;31m70[0m[31m mg effervescent tablet and [0m
[31malendronate sodium [0m[1;31m70[0m[31m mg tablet are bioequivalent. A study evaluating the effect of food on the bioavailability of BINOSTO was performed in [0m[1;31m119[0m[31m healthy women. Bioavailability was decreased [0m[1;31m([0m[31mby [0m
[31mapproximately [0m[1;31m50[0m[31m%[0m[1;31m)[0m[31m when [0m[1;31m70[0m[31m mg alendronate sodium was administered [0m[1;31m15[0m[31m minutes before a standardized breakfast, when compared to dosing [0m[1;31m4[0m[31m hours before eating. In studies of treatment and prevention of [0m
[31mosteoporosis, alendronate was effective when administered at least [0m[1;31m30[0m[31m minutes before breakfast. Bioavailability was negligible whether alendronate sodium was administered with or up to [0m[1;31m2[0m[31m hours after a[0m
[31mstandardized breakfast. Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately [0m[1;31m60[0m[31m%.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new [0m
[31mor worsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m1[0m[31m Upper [0m
[31mGastrointestinal Adverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects [0m
[31mand a potential for worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, [0m
[31mdysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and [0m
[31mrarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe [0m
[31mand required hospitalization. ALENDRONATE SODIUM: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be [0m
[31minstructed to discontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences [0m
[31mappears to be greater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after [0m
[31mdeveloping symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot [0m
[31mcomply with dosing instructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision. ALENDRONATE SODIUM: warnings_and_cautions: There have been post-marketing [0m
[31mreports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials [0m[31m . [0m[1;31m5.2[0m[31m Mineral Metabolism[0m
[31mHypocalcemia must be corrected before initiating therapy with BINOSTO [0m[31m. Other disorders affecting mineral metabolism [0m[1;31m([0m[31msuch as vitamin D deficiency[0m[1;31m)[0m[31m should also be effectively treated. In patients with[0m
[31mthese conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with BINOSTO. Presumably due to the effects of BINOSTO on increasing bone mineral, small, asymptomatic [0m
[31mdecreases in serum calcium and phosphate may occur. Patients should receive adequate calcium and vitamin D intake. [0m[1;31m5[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE BINOSTO is a bisphosphonate indicated for: Treatment of osteoporosis in postmenopausal women [0m[1;31m([0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m)[0m[31m Treatment to increase [0m
[31mbone mass in men with osteoporosis [0m[1;31m([0m[31m [0m[1;31m1.2[0m[31m [0m[1;31m)[0m[31m Limitation of use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after [0m[1;31m3[0m[31m to [0m[1;31m5[0m[31m years [0m
[31mof use [0m[1;31m([0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Treatment of Osteoporosis in Postmenopausal Women BINOSTO effervescent tablet [0m[1;31m70[0m[31m mg is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of [0m
[31mosteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine [0m[1;31m([0m[31mvertebral compression fractures[0m[1;31m)[0m[31m. [0m[1;31m[[0m[31mSee Clinical Studies [0m[1;31m([0m[1;31m14.1[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m1[0m[31m. [0m
[31mALENDRONATE SODIUM: indications_and_usage: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men With Osteoporosis BINOSTO is indicated for treatment to increase bone mass in men with osteoporosis [0m[31m . [0m[1;31m1.3[0m[31m Important[0m
[31mLimitations of Use The optimal duration of use has not been determined. The safety and effectiveness of BINOSTO for the treatment of osteoporosis are based on clinical data of four years duration. All[0m
[31mpatients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after [0m[1;31m3[0m[31m [0m
[31mto [0m[1;31m5[0m[31m years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The provided extracts from the ALENDRONATE SODIUM label do not directly address the risk of hospitalization. However, they do mention that severe esophageal adverse experiences, such as [0m
[32mesophagitis, esophageal ulcers, and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with [0m
[32moral bisphosphonates including alendronate sodium. In some cases, these have been severe and required hospitalization. Therefore, while the medication itself does not inherently increase or decrease [0m
[32mthe risk of hospitalization, incorrect administration or adverse reactions could potentially lead to hospitalization.[0m

[32mSOURCE: ALENDRONATE SODIUM label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32moccasionally with bleeding and rarely followed by[0m[32m...[0m[32mrequired hospitalization.[0m
*[1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The provided extracts from the ALENDRONATE SODIUM label[0m
[34mdo not directly address the risk of hospitalization. However, they do mention that severe esophageal adverse experiences, such as esophagitis, esophageal ulcers, and esophageal erosions, occasionally [0m
[34mwith bleeding and rarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases, [0m
[34mthese have been severe and required hospitalization. Therefore, while the medication itself does not inherently increase or decrease the risk of hospitalization, incorrect administration or adverse [0m
[34mreactions could potentially lead to hospitalization.[0m

[34mSOURCE: ALENDRONATE SODIUM label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34moccasionally with bleeding and rarely followed by[0m[34m...[0m[34mrequired hospitalization.[0m
 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ALENDRONATE SODIUM increases or decreases the risk of hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the ALENDRONATE SODIUM label does not directly address the risk of hospitalization. However, it does mention that severe esophageal adverse experiences, which can [0m
[32moccasionally lead to hospitalization, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The risk of hospitalization is not directly addressed in the context of ALENDRONATE SODIUM use, but severe esophageal adverse experiences associated with its use can occasionally lead [0m
[32mto hospitalization."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ALENDRONATE SODIUM increase or decrease the risk of hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ALENDRONATE SODIUM increases or decreases the risk of hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the ALENDRONATE SODIUM label does not directly address the risk of hospitalization. However, it does mention that severe esophageal adverse experiences, which can [0m
[34moccasionally lead to hospitalization, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The risk of hospitalization is not directly addressed in the context of ALENDRONATE SODIUM use, but severe esophageal adverse experiences associated with its use can occasionally lead [0m
[34mto hospitalization."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ALENDRONATE SODIUM increase or decrease the risk of hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ALENDRONATE SODIUM increases or decreases the risk of hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that the ALENDRONATE SODIUM label does not directly address the risk of hospitalization. However, it does mention that severe esophageal adverse experiences, which can [0m
[31moccasionally lead to hospitalization, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium.[0m
[31m        -----[0m
[31m        Final answer: The risk of hospitalization is not directly addressed in the context of ALENDRONATE SODIUM use, but severe esophageal adverse experiences associated with its use can occasionally[0m
[31mlead to hospitalization.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe risk of hospitalization is not directly addressed in the context of ALENDRONATE SODIUM use, but severe esophageal adverse experiences associated with its use can occasionally lead to [0m
[32mhospitalization.[0m
